Research reading
Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, unmixed, not put up in measured doses or in forms or packings for retail sale demand and the China (CHN) to FIN (FIN) lane
FIN (FIN) reported $5.5M of blood, human or animal, antisera, other blood fractions and immunological products: immunological products, unmixed, not put up in measured doses or in forms or packings for retail sale imports in 2024. China (CHN) accounted for 0.5% of the observed market and reported $27.2K in exports on this lane.
The latest annual values eased slightly, while the longer available history shows +28.6% buyer growth and +131.4% exporter growth. The page separates reported values from projections and indicators.
